Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial

Overview of attention for article published in Lancet Neurology, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 36 X users

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page
guideline: 1 clinical guideline source

Readers on

mendeley: 171 Mendeley

So far, Altmetric has seen 11 news stories from 10 outlets.

Concomitant Clobazam, Valproate Improves Ganaxolone’s Impact on Motor Seizure Frequency in CDKL5 Deficiency Disorder

Neurology Live, 05 Dec 2023

Clobazam and valproate, when used concomitantly, produced a greater treatment effect with ganaxolone than other antseizure…

Ganaxolon: EU-Zulassung für neues Epilepsie-Mittel für Kinder

Pharmazeutische Zeitung, 07 Aug 2023

Das neue Medikament ist indiziert für die zusätzliche Behandlung von epileptischen Anfällen assoziiert mit einem Mangel des…

Rare Seizure Disorder Treatments Continue to Expand

MedPage Today, 06 May 2022

Neurology > Seizures New therapies reduce seizure frequency, but the biggest advancements may be on the horizon by Crystal Phend…

CDKL5 Deficiency Disorder Drug Data Support Modest Benefit

MedPage Today, 28 Apr 2022

Meeting Coverage > AAN Success in rare epileptic disorder may presage broader approvals by John Gever, Contributing Writer…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.